|
|
|||||||||||||||||||||||||
|
VectivBio Holding AG (VECT) VectivBio is a holding company. Through its subsidiaries, Co. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for rare conditions. Co.'s product pipeline is focused on rare gastrointestinal, or GI, disorders. Co. develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy.
|
|
|||||||||||||||||||||||||
Free VECT Email Alerts:
VectivBio Holding AG (VECT) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.